olamkicept

Olamkicept is a first-in-class, selective inhibitor of interleukin-6 (IL‑6) trans-signaling. It is a recombinant fusion protein composed of the extracellular portion of the human gp130 receptor fused to the Fc region of human IgG1. Olamkicept binds specifically to complexes formed by IL‑6 and its soluble receptor (sIL‑6R), thereby neutralizing IL‑6 trans-signaling without affecting classic signaling via membrane-bound IL‑6R. This selectivity allows it to block pro-inflammatory effects mediated by IL‑6 trans-signaling while preserving regenerative and protective functions associated with classic signaling. Olamkicept is being developed primarily for inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease, with clinical trials showing promising efficacy and safety profiles[1][2][3][4][5][7].

Brand names

Olamkicept

Other names

olamkiceptsoluble gp130Fcsgp130Fcsgp-130Fcsgp 130Fc